RxDoctor Payments Data

Tracy Underwood

Family · Kingwood, WVNPI 1174929004

Payments from drug & device makers

$881in general payments, 2019–2025

Across 54 payments — averaging $16.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$377
  • AstraZeneca$197
  • Amgen$101
  • Novo Nordisk$57
  • Lilly USA, LLC$44
  • Boston Scientific$44
  • plus $62 from 2 others

What the payments were for

  • Food & beverage$86999%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie28$377
AstraZeneca11$197
Amgen6$101
Novo Nordisk2$57
Lilly USA, LLC2$44
Boston Scientific2$44
Pfizer2$35
UCB, Inc.1$27

How this compares

$881 in reported general payments places this provider in the 65th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$78,127
Medicare patients
268
Services billed
1,444

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide15$18,674
Tresiba Flextouch U-200Insulin Degludec15$17,323
Albuterol Sulfate HfaAlbuterol Sulfate33$1,025
Oxybutynin Chloride ErOxybutynin Chloride22$691
Atorvastatin Calcium89$686
Pregabalin11$659
Esomeprazole Magnesium13$630
Valsartan11$623
Fluticasone Propionate38$595
Gabapentin38$489
Montelukast Sodium17$446
Omeprazole40$429
Amlodipine Besylate74$389
Losartan Potassium34$380
Rosuvastatin Calcium16$376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$57$18,67415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,507 family providers in West Virginia.

Other family in Kingwood

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →